Abstract | PURPOSE: METHODS AND MATERIALS: From 1999 through 2015, 45 lesions in 21 patients met clinicopathologic pcALCL diagnostic criteria and were treated with RT (<20 Gy, 20-29 Gy, or ≥30 Gy dose). Complete clinical (CR) and partial responses (PR) were compared by dose using Fisher exact test. Progression-free and overall survivals were calculated using the Kaplan-Meier method. RESULTS: Forty-two percent of lesions were treated with <20 Gy, 22% with 20 to 29 Gy, and 35% with ≥30 Gy. Within 12 weeks, 100% responded, with 67% CR and 33% PR; by last follow-up, 87% achieved CR and 13% PR (no difference by RT dose; P = .84). Three-year freedom from local relapse was 100%, 86%, and 100% with <20 Gy, 20 to 29 Gy, and ≥30 Gy, respectively (P = .28). Many patients ultimately demonstrated other cutaneous or systemic relapse, with 55% 3-year and 29% 10-year progression-free survival. Overall survival at 10 years was 59%, with 2 deaths from complications of disease. CONCLUSIONS: Low-dose RT offered excellent local control in the setting of the indolent, chronic course of pcALCL in this patient cohort.
|
Authors | Grace L Smith, Madeleine Duvic, Zeinab Abou Yehia, Pamela Allen, Naveen Garg, Tina Suki, Sarah A Milgrom, Chelsea C Pinnix, Yasuhiro Oki, Joseph D Khoury, Bouthaina S Dabaja |
Journal | Advances in radiation oncology
(Adv Radiat Oncol)
2017 Jul-Sep
Vol. 2
Issue 3
Pg. 363-369
ISSN: 2452-1094 [Print] United States |
PMID | 29114604
(Publication Type: Journal Article)
|